← Back

Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Price · split & dividend adjusted
News & notes moving KURA
KURA

DICK'S Sporting Goods Plunges 30.7% on Q2 Earnings Miss

Shares of DICK'S Sporting Goods plummeted 30.7% after the company reported second-quarter fiscal 2026 earnings of $3.53 per share, missing the Zacks Consensus Estimate of $3.78 per share. In contrast, Kura Oncology's shares jumped 9.6% after CEO Troy Wilson revealed in a regulatory filing that he was buying nearly 100,000 shares of common stock. Navitas Semiconductor gained 1.7% after announcing a deal to acquire Claros for $232.8 million in cash and stock. Walmart's shares declined 1% amid a broader retail decline.
Zacks Investment Research·17hRead more ▾
KURA2

Kura Oncology CEO Buys 100,000 Shares for $1.2 Million

Kura Oncology President, Chairman, and CEO Troy Edward Wilson purchased approximately 100,000 shares of the company's common stock on August 24, 2026, according to an SEC Form 4 filing. The transaction was valued at $1.2 million, based on a weighted average purchase price of $12.39 per share. Following the purchase, Wilson's total beneficial ownership stands at roughly 1.2 million shares, an increase of 9%, with about 435,000 shares held directly and 779,000 held indirectly through the One Fish Two Fish Revocable Trust and the Lorax Charitable Remainder Unitrust. The insider buy comes as the clinical-stage biopharmaceutical company reports trailing twelve-month revenue of $77.2 million and a net loss of $296.8 million, with a market capitalization of $1.1 billion. Wilson has led the company since its founding in 2015, and the purchase is seen as a bullish signal given that insiders typically buy only when they expect the share price to rise.
The Motley Fool·1dRead more ▾
KURA2

Dick's Sporting Goods plunges 27% on revenue miss

Dick's Sporting Goods shares plunged more than 27% after the retailer reported revenue of $5.59 billion, below the $5.65 billion expected by analysts polled by LSEG, citing a challenging footwear market. Dynatrace rose 3% after Morgan Stanley upgraded it to overweight, while Shift4 Payments gained nearly 4% on a Wells Fargo upgrade to overweight. Moderna rallied 13% after Wolfe Research upgraded it to peer perform, and Marvell Technology jumped 5% after Susquehanna and Rosenblatt raised price targets. Advanced Micro Devices gained 5% after Raymond James upgraded it to strong buy with a $641 price target, and Kura Oncology climbed almost 10% after its CEO disclosed buying 100,000 shares. Navitas Semiconductor rose 5% after announcing a $232.8 million deal to acquire Claros.
CNBC·1dRead more ▾